FDA Orphan Drug Designation For Cannabidiol Epilepsy Treatment

Insys Therapeutics, an Arizona-based company with manufacturing facilities in Austin, recently announced that the Food and Drug Administration (FDA) has grantedorphan drug designation for its product, which will provide the therapy with seven years of market exclusivity, among other financial incentives. Insys is producing and commercializing Cannabidiol, a cannabinoid treatment for Dravet syndrome.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *